Sentences with phrase «financial services regulatory»

After NAR members bombarded Senate offices with nearly 2,000 calls, letters, E-mails, and faxes in five days, Sen. Richard Shelby, R - Ala., agreed to strike language from financial services regulatory relief legislation that would have created a huge loophole in the Real Estate Settlement Procedures Act.

As a highly qualified and experienced financial services regulatory attorney specializing in the insurance and reinsurance field, both life and property / casualty, and as a practice team leader in my two most recent law firms, I demonstrate exceptional knowledge of federal, state and international regulatory and compliance issues, transactional acumen, client and employer loyalty, reliability, power of endurance and leaders...

According to the report, there was an initial uncertainty about how digital currencies would fit within the existing «financial services regulatory regime.»

We have teams of litigation and arbitration experts within the firm specialising in financial services regulatory, intellectual property, employment, personal injury, public and regulatory, real estate, tax and technology disputes.

He has 25 years of experience and expertise in financial services regulatory compliance and litigation.

He is set to join the firm as a partner in the magic circle firm's City non-contentious financial services regulatory practice in early 2017.

We are at the forefront of advising financial institutions on how financial services regulatory reform will impact their business.

Ben is co-head of Slaughter and May's Fintech Group and a financial services regulatory lawyer.

Davis Polk's Financial Institutions Group continues to maintain the momentum of its leading - edge thought leadership with a series of microsites that serve as hubs of up - to - the - moment information and analysis on various regulatory matters, such as the financial services regulatory reform, technology and financial innovation, Basel III and blockchain regulation.

Libor was the largest global investigation post-financial crisis, involving antitrust and financial services regulatory elements, and more than 25 regulators in more than 10 countries.

Royce is recognised in Chambers Asia and Asia - Pacific Legal 500 as one of Hong Kong's leading practitioners in the financial services regulatory arena.

Bates Wells Braithwaite is a central London professional services consultancy (ABS) with over 250 staff, combining a top legal practice with services in impact measurement, outcomes - based planning and strategy, and financial services regulatory compliance.

They should anticipate a shift in the dialogue with GCs away from traditional sourcing, and develop modern legal and business solutions for, as examples, financial services regulatory work, HR support, contracting support or due diligence.

Formerly an in - house lawyer in the Hong Kong Securities and Futures Commission's Legal Services Division, Tim is recognised by numerous legal publications as one of Hong Kong's leading contentious and non-contentious practitioners in the financial services regulatory arena.

As a former lecturer at the LSE and a director of the Provident Reliance and the Holloway Friendly Society he has worked in and advised on Financial Services regulatory matters.

She specialises in financial services related disputes and contentious financial services regulatory matters.

financial services regulatory matters in the payments system and cards area (and on the various operating rules and regulations for card networks)

Legal Media Group / Euromoney's IFLR1000 The Guide to the World's Leading Financial Law Firms — Leading Canadian lawyer in capital markets (2008 - 2018), financial services regulatory (2018), banking (2018), financial services (2018)

The firm's practice areas include: banking and finance; corporate and securities; litigation and dispute resolution; antitrust and competition; US Supreme Court and appellate matters; employment and benefits; environmental; financial services regulatory and enforcement; government and global trade; intellectual property; real estate; tax; restructuring, bankruptcy and insolvency; and wealth management.

Financial services regulatory advice — we act for both financial institutions and senior executives of financial institutions, assisting with regulatory investigations, complex issues regarding legal professional privilege, whistleblowing, remuneration structures, the senior managers regime and negotiating exit packages.

Mark Compton is in the financial services regulatory & enforcement practice of Mayer Brown, which, like all firms, has a money laundering reporting officer in London who carries a personal liability for failing to report suspicions or knowledge of money laundering.

We are especially well known for advising financial institutions on financial services regulatory matters.

She specialises in contentious financial services regulatory matters as well as internal investigations.

We have more than 50 partners worldwide with significant contentious and non-contentious financial services regulatory expertise, and a global network of experts advising on the full spectrum of regulatory issues, covering prudential, conduct and enforcement.

Ms. Nazareth has been a key player in financial services regulatory reform for much of her career.

Financial services regulatory expert Andrew Procter is also highly regarded.

The purpose of MiFID II is clear: to provide a strengthened financial services regulatory framework with improved governance and transparency requirements for the benefit of investors.

During the last two years, the Glasgow - based firm has boosted its London offering after a merger with corporate boutique The City Law Partnership and also acquired a majority share of London - based financial services regulatory consultancy Leale - Green.

Barlow Lyde & Gilbert has added to its partnership with a promotion in its City financial services regulatory team.

The departures include the firm's head of marine, energy and trade Patrick Foss, who is joining Norton Rose on 1 November alongside fellow marine insurance partner Chris Zavos, and financial services regulatory partner Chris Brennan, who has left to join Lloyds Banking Group.

June saw the firm hire Washington, DC - based partner Danish Hamid from Cooley's anti-corruption practice, and Michael Silva, a former New York Federal Reserve lawyer, as chair of its financial services regulatory team.

William has over a decade of experience in advising on financial services regulatory matters, both in an advisory and a contentious context.

Charlotte will form part of A&O's global financial services regulatory practice which spans Asia Pacific, Europe,

David and his team advise on a wide range of financial services regulatory and compliance issues.

In that capacity he frequently advised on financial services regulatory issues related transactions, including bond issues and securitisation, and on the development of new financial products.

Reed Smith non-contentious financial services regulatory head Jacqui Hatfield is leaving the firm's City office to join US rival Orrick Herrington & Sutcliffe in London later this year.

With less up for interpretation by investors, what will the impact be on wealth managers in this changing financial services regulatory environment?

Wells Fargo Advisors is registered with the U.S. Securities and Exchange Commission and the Financial Industry Regulatory Authority, but is not licensed or registered with any financial services regulatory authority outside of the U.S. Non-U.S. residents who maintain U.S. - based financial services account (s) with Wells Fargo Advisors may not be afforded certain protections conferred by legislation and regulations in their country of residence in respect of any investments, investment transactions or communications made with Wells Fargo Advisors.

Not exact matches

«We believe that — for a number of reasons — putting in place appropriate regulatory safeguards for virtual currencies will be beneficial to the long term strength of the virtual currency industry,» Benjamin Lawsky, New York's superintendent for financial services, wrote in a draft memo reviewed by the Journal.

In the last year, Trump rolled back regulations on environmental protections, financial services, and health care, calling it the «most far - reaching regulatory reform» in U.S. history.

Such risks, uncertainties and other factors include, without limitation: (1) the effect of economic conditions in the industries and markets in which United Technologies and Rockwell Collins operate in the U.S. and globally and any changes therein, including financial market conditions, fluctuations in commodity prices, interest rates and foreign currency exchange rates, levels of end market demand in construction and in both the commercial and defense segments of the aerospace industry, levels of air travel, financial condition of commercial airlines, the impact of weather conditions and natural disasters and the financial condition of our customers and suppliers; (2) challenges in the development, production, delivery, support, performance and realization of the anticipated benefits of advanced technologies and new products and services; (3) the scope, nature, impact or timing of acquisition and divestiture or restructuring activity, including the pending acquisition of Rockwell Collins, including among other things integration of acquired businesses into United Technologies» existing businesses and realization of synergies and opportunities for growth and innovation; (4) future timing and levels of indebtedness, including indebtedness expected to be incurred by United Technologies in connection with the pending Rockwell Collins acquisition, and capital spending and research and development spending, including in connection with the pending Rockwell Collins acquisition; (5) future availability of credit and factors that may affect such availability, including credit market conditions and our capital structure; (6) the timing and scope of future repurchases of United Technologies» common stock, which may be suspended at any time due to various factors, including market conditions and the level of other investing activities and uses of cash, including in connection with the proposed acquisition of Rockwell; (7) delays and disruption in delivery of materials and services from suppliers; (8) company and customer - directed cost reduction efforts and restructuring costs and savings and other consequences thereof; (9) new business and investment opportunities; (10) our ability to realize the intended benefits of organizational changes; (11) the anticipated benefits of diversification and balance of operations across product lines, regions and industries; (12) the outcome of legal proceedings, investigations and other contingencies; (13) pension plan assumptions and future contributions; (14) the impact of the negotiation of collective bargaining agreements and labor disputes; (15) the effect of changes in political conditions in the U.S. and other countries in which United Technologies and Rockwell Collins operate, including the effect of changes in U.S. trade policies or the U.K.'s pending withdrawal from the EU, on general market conditions, global trade policies and currency exchange rates in the near term and beyond; (16) the effect of changes in tax (including U.S. tax reform enacted on December 22, 2017, which is commonly referred to as the Tax Cuts and Jobs Act of 2017), environmental, regulatory (including among other things import / export) and other laws and regulations in the U.S. and other countries in which United Technologies and Rockwell Collins operate; (17) the ability of United Technologies and Rockwell Collins to receive the required regulatory approvals (and the risk that such approvals may result in the imposition of conditions that could adversely affect the combined company or the expected benefits of the merger) and to satisfy the other conditions to the closing of the pending acquisition on a timely basis or at all; (18) the occurrence of events that may give rise to a right of one or both of United Technologies or Rockwell Collins to terminate the merger agreement, including in circumstances that might require Rockwell Collins to pay a termination fee of $ 695 million to United Technologies or $ 50 million of expense reimbursement; (19) negative effects of the announcement or the completion of the merger on the market price of United Technologies» and / or Rockwell Collins» common stock and / or on their respective financial performance; (20) risks related to Rockwell Collins and United Technologies being restricted in their operation of their businesses while the merger agreement is in effect; (21) risks relating to the value of the United Technologies» shares to be issued in connection with the pending Rockwell acquisition, significant merger costs and / or unknown liabilities; (22) risks associated with third party contracts containing consent and / or other provisions that may be triggered by the Rockwell merger agreement; (23) risks associated with merger - related litigation or appraisal proceedings; and (24) the ability of United Technologies and Rockwell Collins, or the combined company, to retain and hire key personnel.

The proposed delay should have a «calming» effect on the marketplace, which had been «hanging in limbo» ahead of the April 10 effective date, said Denise Valentine, a senior analyst with Aite Group, which advises the financial services industry on regulatory issues.

«Our economic infrastructure lives in a digital space, which means leveraging big data to streamline financial services to keep information secure, while also well organized and transparent, making it accessible for regulatory bodies,» says Teijeiro.

With 22 years of financial services, legal, operations, risk, and regulatory experience, she has been a key contributor to Mellon Capital's international expansion.

Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward - looking statements include, among others, the following: our ability to successfully and profitably market our products and services; the acceptance of our products and services by patients and healthcare providers; our ability to meet demand for our products and services; the willingness of health insurance companies and other payers to cover Cologuard and adequately reimburse us for our performance of the Cologuard test; the amount and nature of competition from other cancer screening and diagnostic products and services; the effects of the adoption, modification or repeal of any healthcare reform law, rule, order, interpretation or policy; the effects of changes in pricing, coverage and reimbursement for our products and services, including without limitation as a result of the Protecting Access to Medicare Act of 2014; recommendations, guidelines and quality metrics issued by various organizations such as the U.S. Preventive Services Task Force, the American Cancer Society, and the National Committee for Quality Assurance regarding cancer screening or our products and services; our ability to successfully develop new products and services; our success establishing and maintaining collaborative, licensing and supplier arrangements; our ability to maintain regulatory approvals and comply with applicable regulations; and the other risks and uncertainties described in the Risk Factors and in Management's Discussion and Analysis of Financial Condition and Results of Operations sections of our most recently filed Annual Report on Form 10 - K and our subsequently filed Quarterly Reports on Forfinancial condition to differ materially from those indicated in the forward - looking statements include, among others, the following: our ability to successfully and profitably market our products and services; the acceptance of our products and services by patients and healthcare providers; our ability to meet demand for our products and services; the willingness of health insurance companies and other payers to cover Cologuard and adequately reimburse us for our performance of the Cologuard test; the amount and nature of competition from other cancer screening and diagnostic products and services; the effects of the adoption, modification or repeal of any healthcare reform law, rule, order, interpretation or policy; the effects of changes in pricing, coverage and reimbursement for our products and services, including without limitation as a result of the Protecting Access to Medicare Act of 2014; recommendations, guidelines and quality metrics issued by various organizations such as the U.S. Preventive Services Task Force, the American Cancer Society, and the National Committee for Quality Assurance regarding cancer screening or our products and services; our ability to successfully develop new products and services; our success establishing and maintaining collaborative, licensing and supplier arrangements; our ability to maintain regulatory approvals and comply with applicable regulations; and the other risks and uncertainties described in the Risk Factors and in Management's Discussion and Analysis of Financial Condition and Results of Operations sections of our most recently filed Annual Report on Form 10 - K and our subsequently filed Quarterly Reports on Formservices; the acceptance of our products and services by patients and healthcare providers; our ability to meet demand for our products and services; the willingness of health insurance companies and other payers to cover Cologuard and adequately reimburse us for our performance of the Cologuard test; the amount and nature of competition from other cancer screening and diagnostic products and services; the effects of the adoption, modification or repeal of any healthcare reform law, rule, order, interpretation or policy; the effects of changes in pricing, coverage and reimbursement for our products and services, including without limitation as a result of the Protecting Access to Medicare Act of 2014; recommendations, guidelines and quality metrics issued by various organizations such as the U.S. Preventive Services Task Force, the American Cancer Society, and the National Committee for Quality Assurance regarding cancer screening or our products and services; our ability to successfully develop new products and services; our success establishing and maintaining collaborative, licensing and supplier arrangements; our ability to maintain regulatory approvals and comply with applicable regulations; and the other risks and uncertainties described in the Risk Factors and in Management's Discussion and Analysis of Financial Condition and Results of Operations sections of our most recently filed Annual Report on Form 10 - K and our subsequently filed Quarterly Reports on Formservices by patients and healthcare providers; our ability to meet demand for our products and services; the willingness of health insurance companies and other payers to cover Cologuard and adequately reimburse us for our performance of the Cologuard test; the amount and nature of competition from other cancer screening and diagnostic products and services; the effects of the adoption, modification or repeal of any healthcare reform law, rule, order, interpretation or policy; the effects of changes in pricing, coverage and reimbursement for our products and services, including without limitation as a result of the Protecting Access to Medicare Act of 2014; recommendations, guidelines and quality metrics issued by various organizations such as the U.S. Preventive Services Task Force, the American Cancer Society, and the National Committee for Quality Assurance regarding cancer screening or our products and services; our ability to successfully develop new products and services; our success establishing and maintaining collaborative, licensing and supplier arrangements; our ability to maintain regulatory approvals and comply with applicable regulations; and the other risks and uncertainties described in the Risk Factors and in Management's Discussion and Analysis of Financial Condition and Results of Operations sections of our most recently filed Annual Report on Form 10 - K and our subsequently filed Quarterly Reports on Formservices; the willingness of health insurance companies and other payers to cover Cologuard and adequately reimburse us for our performance of the Cologuard test; the amount and nature of competition from other cancer screening and diagnostic products and services; the effects of the adoption, modification or repeal of any healthcare reform law, rule, order, interpretation or policy; the effects of changes in pricing, coverage and reimbursement for our products and services, including without limitation as a result of the Protecting Access to Medicare Act of 2014; recommendations, guidelines and quality metrics issued by various organizations such as the U.S. Preventive Services Task Force, the American Cancer Society, and the National Committee for Quality Assurance regarding cancer screening or our products and services; our ability to successfully develop new products and services; our success establishing and maintaining collaborative, licensing and supplier arrangements; our ability to maintain regulatory approvals and comply with applicable regulations; and the other risks and uncertainties described in the Risk Factors and in Management's Discussion and Analysis of Financial Condition and Results of Operations sections of our most recently filed Annual Report on Form 10 - K and our subsequently filed Quarterly Reports on Formservices; the effects of the adoption, modification or repeal of any healthcare reform law, rule, order, interpretation or policy; the effects of changes in pricing, coverage and reimbursement for our products and services, including without limitation as a result of the Protecting Access to Medicare Act of 2014; recommendations, guidelines and quality metrics issued by various organizations such as the U.S. Preventive Services Task Force, the American Cancer Society, and the National Committee for Quality Assurance regarding cancer screening or our products and services; our ability to successfully develop new products and services; our success establishing and maintaining collaborative, licensing and supplier arrangements; our ability to maintain regulatory approvals and comply with applicable regulations; and the other risks and uncertainties described in the Risk Factors and in Management's Discussion and Analysis of Financial Condition and Results of Operations sections of our most recently filed Annual Report on Form 10 - K and our subsequently filed Quarterly Reports on Formservices, including without limitation as a result of the Protecting Access to Medicare Act of 2014; recommendations, guidelines and quality metrics issued by various organizations such as the U.S. Preventive Services Task Force, the American Cancer Society, and the National Committee for Quality Assurance regarding cancer screening or our products and services; our ability to successfully develop new products and services; our success establishing and maintaining collaborative, licensing and supplier arrangements; our ability to maintain regulatory approvals and comply with applicable regulations; and the other risks and uncertainties described in the Risk Factors and in Management's Discussion and Analysis of Financial Condition and Results of Operations sections of our most recently filed Annual Report on Form 10 - K and our subsequently filed Quarterly Reports on FormServices Task Force, the American Cancer Society, and the National Committee for Quality Assurance regarding cancer screening or our products and services; our ability to successfully develop new products and services; our success establishing and maintaining collaborative, licensing and supplier arrangements; our ability to maintain regulatory approvals and comply with applicable regulations; and the other risks and uncertainties described in the Risk Factors and in Management's Discussion and Analysis of Financial Condition and Results of Operations sections of our most recently filed Annual Report on Form 10 - K and our subsequently filed Quarterly Reports on Formservices; our ability to successfully develop new products and services; our success establishing and maintaining collaborative, licensing and supplier arrangements; our ability to maintain regulatory approvals and comply with applicable regulations; and the other risks and uncertainties described in the Risk Factors and in Management's Discussion and Analysis of Financial Condition and Results of Operations sections of our most recently filed Annual Report on Form 10 - K and our subsequently filed Quarterly Reports on Formservices; our success establishing and maintaining collaborative, licensing and supplier arrangements; our ability to maintain regulatory approvals and comply with applicable regulations; and the other risks and uncertainties described in the Risk Factors and in Management's Discussion and Analysis of Financial Condition and Results of Operations sections of our most recently filed Annual Report on Form 10 - K and our subsequently filed Quarterly Reports on ForFinancial Condition and Results of Operations sections of our most recently filed Annual Report on Form 10 - K and our subsequently filed Quarterly Reports on Form 10 - Q.

Here's the company's response to the state's chief financial regulatory body: «Symphony is built on a foundation of security, compliance and privacy features that were built to enable our financial services and enterprise customers to meet their regulatory requirements.

But he gave up that position in 2013 to take the gavel on the House Financial Services Committee, which has allowed him to reshape regulatory policy.

How will the acceleration of technology, shifting customer preferences, and an evolving regulatory landscape impact the design and delivery of financial services?

According to reports, Japan's Financial Services Agency, a regulatory body, is informally encouraging cryptocurrency exchanges in the country to delist Monero, Zcash, and Dash, all of which are so - called privacy coins.

The new regulatory body will reportedly oversee exchanges registered with Japan's Financial Services Association.